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Abstract 7 
Drug delivery to the body via the inhaled route is dependent upon patient status, device use and respirable 8 
formulation characteristics.  Further to inhalation, drug-containing particles interact and dissolve within 9 
pulmonary fluid leading to the desired pharmacological response.  Pulmonary surfactant stabilises the alveolar 10 
air-liquid interface and permits optimal respiratory mechanics.  This material represents the initial contacting 11 
surface for all inhaled matter.  On dissolution, the fate of a drug substance can include receptor activation, 12 
membrane partitioning and cellular penetration.  Here, we consider the partitioning behaviour of salbutamol 13 
when located in proximity to a simulated pulmonary surfactant monolayer at pH 7.  The administration of 14 
salbutamol to the underside of the surfactant film resulted in an expanded character for the two-dimensional 15 
ensemble and a decrease in the compressibility term.  The rate of drug partitioning was greater when the 16 
monolayer was in the expanded state (i.e. inhalation end-point), which was ascribed to more accessible areas 17 
for molecular insertion.  Quantum mechanics protocols, executed via Gaussian 09, indicated that constructive 18 
interactions between salbutamol and integral components of the model surfactant film took the form of 19 
electrostatic and hydrophobic associations.  The favourable interactions are thought to promote drug insertion 20 
into the monolayer structure leading to the observed expanded character.  The data presented herein confirm 21 
that drug partitioning into pulmonary surfactant monolayers is a likely prospect further to the inhalation of 22 
respirable formulations.  As such, this process holds potential to reduce drug-receptor activation and / or 23 
increase the residence time of drug within the pulmonary space.  24 
 25 
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1. Introduction 40 
 41 
The respiratory system can be principally divided into two regions, namely the upper and lower 42 
airways.  The former marks the point of entry for atmospheric gases, respirable formulations and 43 
environmental toxins, whilst the latter is the primary site for gaseous exchange and holds the potential 44 
to be exploited for drug (i.e. insulin and analgesic) delivery to the systemic circulation [1].  Drug 45 
deposition within the respiratory tract as a whole is dependent on a number of factors including for 46 
instance inhaler technique, patient co-morbidities, device structure and function plus formulation 47 
characteristics (i.e. drug particle size, shape, density, surface energetics and external chemistries) [2].  48 
Typically, the dose of medicine physically delivered to the lung on device activation is within the region 49 
of 20% of that emitted at source [3].  At the early stage of the drug delivery process, the aerodynamic 50 
particle size of the solid material heavily influences deposition patterns.  For example, those particles 51 
of diameter 5µm or less hold a good chance of deep lung deposition with drug particles of less than 52 
3µm diameter able to reach the alveolar space [4].  Following delivery to the deep lung and related 53 
interaction with the respective internal surfaces, individual drug-containing particles and solubilised 54 
drug molecules must overcome a number of barriers (e.g. pulmonary surfactant and the lung epithelial 55 
layer) and processes (e.g. mucociliary clearance and partitioning) prior to local or systemic activity [5].  56 
A robust understanding of the fate of inhaled therapies, and of particular relevance to the work 57 
presented herein drug partitioning within pulmonary surfactant monolayers, can inform the drug 58 
design process and consequently lead to improved respirable formulations.   59 
Pulmonary surfactant is central to effective respiratory mechanics.  This endogenous material bathes 60 
the alveolar air-liquid interface and preserves airway patency by reducing the work of breathing [6]. 61 
In addition, the substance protects the lung from invading microorganisms, environmental toxins and 62 
particles inhaled from the atmosphere by promoting the process of mucociliary clearance [7].  The 63 
lipid element of pulmonary surfactant accounts for 90% of the blend and consists of several species 64 
such as phosphatidylcholines (PC), unsaturated phosphatidylglycerols (POPG) along with cholesterol, 65 
fatty acids and triglycerides plus palmitic acid (PA).  Dipalmitoylphosphatidylcholine (DPPC) is the most 66 
abundant phospholipid within pulmonary surfactant, ranging from between 40% - 80% by weight [8].  67 
This particular species packs tightly at the interface and reduces surface tension to near zero values 68 
from the maximum surface pressure of 70mN/m [8].  Surfactant specific proteins (SP) account for the 69 
remaining 10% of the mixture and include SP-A, SP-B, SP-C and SP-D; all differ in molecular weight, 70 
size and function [7].  71 
 72 
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Detailed discussion regarding the chemistries of key components of model pulmonary surfactant (i.e. 73 
DPPC, POPG and PA) [9] has been provided elsewhere [10], hence consideration will be limited here.  74 
In brief, the DPPC molecule exists as a zwitterion at physiological pH [11] and includes two saturated 75 
acyl chains which assemble through hydrophobic interactions into gel-like condensed phases [12]. The 76 
quaternary ammonium group that holds a permanent charge can act as a non-classical hydrogen bond 77 
donor.  In addition, a hydrogen bond acceptor is present within the molecule as a result of the 78 
negatively charged phosphate group; unlike the positive charge, the negative charge is pH dependant.  79 
Post compression, DPPC is unable to reform the monolayer rapidly as high surface pressures promote 80 
the solid state.  Therefore, additional lipid species are required to improve and facilitate material 81 
respread during inspiratory phases [8]  Indeed, this particular point has been highlighted by 82 
Veldhuizen and co-workers who demonstrated that DPPC:PG mixtures increased adsorption activity 83 
compared to single component mixtures alone [13].  In relation to this, it is widely acknowledged that 84 
surfactant specific proteins are central in promoting material respread, adsorption and stabilisation 85 
of the surface film during the breathing process [14].  The 1-palmitoyl-2-oleyl-phosphatidylglycerol 86 
(POPG) molecule is an unsaturated anionic phospholipid that increases the fluidity of a two-87 
dimensional surfactant film and enhances adsorption at the air-liquid interface post compression.  This 88 
fluidising agent has a similar chemical structure to DPPC, however the quaternary ammonium group 89 
is replaced with two hydroxyl groups and bears one negative charge per molecule in the form of a 90 
phosphate group [10].  Palmitic acid is composed of a 16-carbon acyl chain that makes up the fatty 91 
acid component of some phospholipids and improves the surface properties of the surfactant, 92 
especially DPPC.  This particular molecule is a long chain saturated fatty acid with a terminal carboxylic 93 
acid group.  The species enhances the rigidity of a pulmonary surfactant monolayer at low surface 94 
tensions and facilitates respreading; thus supporting its inclusion within model pulmonary surfactant 95 
formulations considered in this work [9].  96 
The application of Langmuir monolayer technology to study pulmonary surfactant relies upon the 97 
careful arrangement of amphiphilic molecules across the surface of an aqueous subphase such that 98 
the hydrocarbon chain components direct themselves towards the gaseous phase (i.e. air) and related 99 
polar functionalities penetrate into the liquid phase (i.e. ultrapure water). Once established, scope 100 
exists to apply lateral forces to the surfactant film either in isolation (i.e. Langmuir isotherm) or in 101 
rapid succession (i.e. Langmuir isocycle) to probe structure-function activity.  Interestingly, 102 
opportunity also presents to hold the surfactant molecules in a fixed position at a particular target 103 
pressure and observe the impact of molecular interactions on material dynamics over time.   104 
 105 
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Such Langmuir surface pressure – time plots, leading to penetration pressure – time data series, can 106 
be readily applied to better understand the interaction between drug molecules dissolved within the 107 
supporting subphase and the two-dimensional ensemble under investigation (i.e. to assist in the 108 
determination of drug partitioning behaviour within a simulated pulmonary space). 109 
Drug partitioning is the distribution of therapeutic molecules between two immiscible phases, where 110 
an aqueous solution is usually present [15].  The ability to achieve certain concentrations in different 111 
phases underpins diffusion of molecules which is fundamental in the process of drug delivery to the 112 
body and in particular drug absorption leading to a therapeutic response.  Clearly, the degree to which 113 
drug partitioning occurs is dependent on the properties of the surrounding phases and respective 114 
chemical components.  Most drug molecules may be ionised in solution resulting in either anionic, 115 
cationic, zwitterionic or neutral forms; the extent of which depends on the acidity or basicity of the 116 
drug and relative pH of the solution.  Naturally, the ionisation state of a therapeutic molecule can 117 
significantly impinge upon the partition index (i.e. in terms of lipid solubility within a surfactant film 118 
moving from solvent water).  Additional factors that may influence drug partitioning include the size, 119 
shape and concentration of the drug molecule itself [16].  To date, relatively few studies have 120 
considered drug (in the present case salbutamol sulphate) penetration into simulated pulmonary 121 
surfactant monolayers and rationalised the resultant biological outcomes.  This fact may be ascribed 122 
to the inherent complexity of the systems involved [15].  However, applied research in this field is 123 
possible with evidence emerging that drug partitioning within such a space can occur via unassisted 124 
thermodynamic mechanisms.  For example, in 1998 Krill and colleagues highlighted that initial 125 
penetration and subsequent partitioning of a drug into a two-dimensional lipid film can be either 126 
enthalpically or entropically driven, or indeed both [17].   127 
Salbutamol sulphate is widely prescribed within the United Kingdom for the management of asthma 128 
and chronic obstructive pulmonary disease (COPD) [18].  This theƌapeutiĐ ageŶt is a shoƌt aĐtiŶg β2-129 
adrenergic receptor agonist that initiates relaxation of bronchial smooth muscle post administration 130 
[3].  The onset of action following inhalation is typically 5 minutes and the therapeutic effect normally 131 
remains for between 3 and 5 hours [18]. The recommended daily inhaled dose of salbutamol sulphate 132 
is usually 100mcg – 200mcg up to four times a day, as required [18].  The high seleĐtiǀity foƌ β2-133 
adrenoceptors may be ascribed to the N-t-butyl group within the molecule, as detailed in Figure 1 134 
[19].  135 
 136 
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 137 
Figure 1. The molecular structure of salbutamol.  138 
Salbutamol presents as a racemic mixture, where the R-isomer is pharmacologically active and holds 139 
high affinity for β2-adrenoceptors as compared to the S-isomer [11].  The chemical stability of 140 
salbutamol sulphate can be affected by pH, elevated temperatures and buffer solutions.  As the 141 
ionisation state of salbutamol varies with pH, the molecule can exist in either a zwitterionic or cationic 142 
form having the two pKa values of 9.3 (i.e. amino) or 10.3 (i.e. phenolic), respectively [11, 20].  143 
Protonation of the nitrogen atom within the salbutamol structure can promote ionic bond formation 144 
with negatively charged functionalities of neighbouring molecules (i.e. phosphate groupings available 145 
within nearby DPPC and POPG surfactant species).  Furthermore, hydrogen bonds may also form with 146 
the phenolic groups in salbutamol.  147 
Surface electrostatic potentials relating to therapeutic drug molecules of interest (i.e. salbutamol) and 148 
the polar regions of amphiphilic molecules located at the alveolar air-liquid interface (i.e. DPPC, POPG 149 
and PA) may be determined via the execution of quantum mechanics protocols.  Indeed, such 150 
calculations have been successfully applied in recent studies conducted by Clark and co-workers 151 
during 2007 [21] plus Davies and colleagues in 2017 [10].  The understanding gained can further our 152 
appreciation of how interacting moieties arrange themselves when in close proximity to each other 153 
and how such arrangement can dictate drug impact on system function and activity within the body.  154 
Density functional theory can provide electrostatics of sufficient accuracy to explain drug-surface 155 
interactions [22].  Accordingly, this approach will be applied to rationalise information obtained from 156 
Langmuir monolayer studies such that deviations in isotherms / isocycles from the baseline can be 157 
mechanistically explained. 158 
This study aims to investigate the partitioning behaviour of our model therapeutic agent salbutamol 159 
sulphate when injected to the underside of simulated pulmonary surfactant monolayers at pH 7.  160 
Associated molecular modelling will be conducted to rationalise key interactions at the molecular 161 
level.  The results obtained will be related to the fate of drug entities on delivery to the respiratory 162 
tract. 163 
 164 
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2. Materials and Methods 165 
 166 
2.1 Materials 167 
 168 
Salbutamol sulphate was purchased from BUFA Chemicals, Germany (Charge: 13K26-B07-296570.  169 
Art. Nr. 13010).  The surfactants DPPC (BN: 160PC-319) and POPG (BN: 160-181PG-137) were obtained 170 
from Avanti Polar Lipids, USA, whilst PA was acquired from Sigma-Aldrich, UK (BN: 087K1877).  The 171 
materials were of analytical grade and used as supplied.  Chloroform (CHCl3) was also of analytical 172 
grade (≥ ϵϵ.ϵ%) and purchased from Fischer Scientific, UK (BN: 1693191).  This solution was employed 173 
to dissolve the surface active material to form the Langmuir trough spreading solution and for all 174 
cleaning procedures.  Ultrapure water (Purite, UK), of resistivity ϭϴ.MΩĐŵ, ǁas used ďoth duƌiŶg 175 
cleaning procedures and as the aqueous subphase during all Langmuir monolayer work. 176 
 177 
2.2 Method 178 
 179 
2.2.1 Langmuir Monolayers 180 
 181 
 182 
Simulated pulmonary surfactant monolayers were generated using a Langmuir trough (Model 102M, 183 
Nima Technology, UK). Surfactant-free Kimtech tissues (Kimtech Science, Kimberley-Clark 184 
Professional, 75512, UK) were soaked in chloroform and used to clean all the glassware and contacting 185 
surfaces.  Trough cleanliness was confirmed by application of surface pressure test runs, where a value 186 
of 0.4mN/m (or less) at full barrier compression confirmed suitability.  A chloroform-based spreading 187 
solution composed of DPPC, POPG and PA in the ratio 69:20:11 was produced at a concentration of 188 
1mg/ml [9].  Subsequently, a volume of 15µl of the spreading solution was applied to the surface of 189 
the aqueous subphase by drop-wise addition and a period of 10 minutes allowed to enable monolayer 190 
settling.  The Langmuir trough barriers were set to move to the centre of the trough at a rate of 191 
25cm2/min in the case of isotherm plots.  With regard to Langmuir isocycle data, the barrier system 192 
was programmed to operate at 100cm2/min.  Surface pressure vs percentage trough area readings 193 
under ambient conditions (i.e. 20°C  1°C) were collected using a Wilhelmy plate at the centre of the 194 
compartment. 195 
 196 
 197 
 198 
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To examine the rate of drug partitioning with respect to time, the target pressures of 10mN/m (i.e. 199 
inhalation end-point) and 50mN/m (i.e. exhalation end-point) were established and left to stand for 200 
one hour.  Here, the first 5 minutes were used to condition the monolayer and salbutamol sulphate 201 
was then injected underneath the monolayer at the 5th minute, as detailed in the following section.  202 
Data was then acquired after the 10th minute to allow the monolayer to settle upon addition of the 203 
drug.  All data were acquired in triplicate and the standard error of the mean calculated accordingly.  204 
The analysis of covariance was elucidated in order to test for significance within the time-based data 205 
sets. 206 
2.2.2   Salbutamol Sulphate Administration to Simulated Pulmonary Surfactant Monolayers 207 
 208 
Initially, 2mg of salbutamol sulphate was accurately weighed and then dissolved in 1ml of ultrapure 209 
water to obtain a stock solution of concentration 2mg/ml.  This drug-containing solution was 210 
suďseƋueŶtly diluted 5 tiŵes ďy ƌeŵoǀiŶg ϭϬϬμl of solution aŶd addiŶg this to ϵϬϬμl of ultƌapuƌe 211 
water.  On completion of this process, the concentration of the final salbutamol sulphate solution was 212 
0.02mcg/ml.  Further to a period of 10 minutes for mixed surfactant monolayer spreading, the pre-213 
prepared salbutamol-containing solution was delivered to the underside of the two-dimensional film 214 
(i.e. to reflect drug availability post particle dissolution).  Here, a volume of 5ϬϬμl of the diluted 215 
salbutamol solution was added to either side of the compartment underneath the trough barriers.  On 216 
delivery a period of 10 minutes allowed the drug to distribute evenly within the supporting subphase 217 
and interact within the simulated pulmonary surfactant monolayer.  Langmuir isotherms, isocycles 218 
and surface pressure – time data were then generated for each system under investigation.  Each 219 
investigation was repeated in triplicate with the standard error of the mean in turn calculated. 220 
To investigate dose response effects, individual Langmuir isotherms and isocycles were obtained with 221 
concentrations of 0.01mcg/ml, 0.02mcg/ml and 0.04mcg/ml of salbutamol; where a total of 1mg, 2mg 222 
and 4mg were diluted 5 times as previously described.  In this case, the dose conversion from 200mcg 223 
(i.e. two standard doses) to 0.02mcg/ml was calculated as a factor of the surface area of the Langmuir 224 
trough.  Here, the Langmuir trough area was 70cm2, whilst the surface area of the lung is recognised 225 
to be 70m2 [23]. 226 
 227 
 228 
 229 
 230
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2.2.3 Langmuir Monolayer Analysis 231 
 232 
2.2.3.1 Compressibility 233 
 234 
The compressibility term relates to the ability of a surfactant film to reduce the surface tension term 235 
with minimal transformation to surface area [24].  An ideal lung surfactant should have a low 236 
compressibility value as this indicates the rigidness of the monolayer which represents in vivo 237 
conditions [25].  To calculate the compressibility term, Equation 1 was employed. 238 
 239 
Compressibility = 
ଵ� � ଵ� 240 
 241 
Equation 1. Calculation of the compressibility of the monolayer. 242 
 243 
Wheƌe A ƌepƌeseŶts the ƌelatiǀe suƌfaĐe aƌea aŶd ŵ the slope of the isotheƌŵ. Heƌe, ͚ ŵ͛ ǁas ĐalĐulated 244 
usiŶg ͚ŵ = ௬ଶ−௬ଵ௫ଶ−௫ଵ͛, ďetǁeeŶ 5Ϭ% and 80% of the Langmuir trough area.   245 
 246 
2.2.3.2 Statistical Analysis 247 
 248 
With respect to Langmuir surface pressure - time data, statistical analysis involved application of 249 
analysis of covariance using Minitab v17 [26].  This software was utilised to compare the mean of each 250 
data point with time and pressuƌe. Heƌe, a ͚p͛ ǀalue of <Ϭ.Ϭ5 ǁas used to demonstrate significance.  251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
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2.2.4 Molecular Modelling 266 
 267 
 268 
In order to rationalise drug partitioning behaviour in proximity to simulated pulmonary surfactant 269 
monolayers, system components were studied at the RHF/6-31G* level via Gaussian09 [27, 28, 29, 270 
30].  Conformations of the key elements for molecular recognition at the underside of the surfactant 271 
monolayer (i.e. excluding the more external hydrocarbon chain groupings) were generated using 272 
omega [31].  Following geometry optimisation, the electron density was visualised in Gaussview [32].  273 
Here, the electrostatic potential is projected onto a surface of constant electron density using default 274 
values.  Representations of the projected electrostatic potential were generated from two opposing 275 
sides. The resultant output was the generation of a number of images that reflect all of the entities 276 
that could potentially interact at the test interface.   277 
 278 
3 Results and Discussion 279 
 280 
 281 
During this work we have applied a mixed surfactant monolayer composed of primary lipid species of 282 
the lung (i.e. DPPC, POPG and PA) to represent the alveolar air-liquid interface within the laboratory 283 
setting.  Throughout, the dynamic interplay between constituents of the thin lipid films and drug 284 
molecules was considered.  The overarching intention was to determine the mechanism(s) of 285 
salbutamol interaction with simulated pulmonary surfactant monolayers and hence better 286 
understand drug partitioning behaviour further to delivery to the respiratory tract. 287 
 288 
3.1 Langmuir Isotherms   289 
 290 
Langmuir pressure-area (π-A) isotherms of the mixed monolayer system following exposure to 291 
increased concentrations of salbutamol sulphate are presented in Figure 2.    292 
 293 
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 294 
Figure 2. Langmuir π-A isotherms for the mixed surfactant system supported on an ultrapure water subphase 295 
with increased concentrations of salbutamol sulphate at pH 7.  In each case, a total of 3 repeats were acquired 296 
to enable the presentation of average values with error bars representing one standard error in the mean.   All 297 
experiments were conducted at a temperature of 20°C  1oC. 298 
On inspection of the data presented in Figure 2, it is evident that compression of the mixed monolayer 299 
system led to an increase in the surface pressure term throughout.  In all cases smooth traces are 300 
apparent and are in line with previously acquired data [10].   Clear gradient changes within each curve 301 
reflect phase transitions within the two-dimensional ensemble [33].  Baseline data confirmed that the 302 
mixed surfactant film attained a maximum surface pressure of 49mN/m.  However, this value 303 
increased upon salbutamol sulphate addition to the supporting aqueous subphase; the maximum 304 
surface pressure was above 54mN/m, for all concentrations of salbutamol sulphate that were studied.  305 
The apparent increase in the surface pressure term was attributed to the drug contribution at the air-306 
liquid interface within the test zone. 307 
Administration of salbutamol sulphate to the mixed surfactant monolayer caused a change to the 308 
Langmuir isotherm shape when compared to the baseline.  Here, expansion of the two-dimensional 309 
ensemble is consistently demonstrated, being concentration dependent.  The delivery of 0.01mcg 310 
salbutamol sulphate to the test zone resulted in monolayer expansion, with a maximum surface 311 
pressure of 54.3mN/m recorded; a comparable value to the 0.02mcg/ml addition.  Whilst the delivery 312 
of 0.04mcg/ml salbutamol sulphate to the supporting aqueous media resulted in an increase in the 313 
surface pressure term to 55.1mN/m.  This equates to a 1.5% increase in maximum surface pressure 314 
from the addition of 0.02 mcg of salbutamol.  The Langmuir isotherm data also indicate that as the 315 
concentration of salbutamol sulphate increases, the curve plateau point is realised at an earlier stage.  316 
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For doses 0.01mcg, 0.02mcg and 0.04mcg the isotherm starts to plateau at trough areas of 35%, 40% 317 
and 50% which confirms a greater solid phase contribution to monolayer dynamics. 318 
On consideration of the compressibility term, a decrease in the descriptor was evident on increasing 319 
salbutamol sulphate concentration as outlined in Table 1 (e.g. the addition of 0.04 mcg/ml caused an 320 
approximate 70% reduction from the baseline value).  The clear reduction in this parameter confirms 321 
that as the number of drug molecules increase, the two-dimensional film becomes more rigid and less 322 
compressible.  323 
 324 
 325 
 326 
 327 
 328 
 329 
Table 1. Compressibility values (mN/m) of the Langmuir surface pressure isotherms. 330 
Drug insertion into a surfactant film influences lipid packing and hence system dynamics.  Here, the 331 
addition of salbutamol sulphate to the underside of the pulmonary surfactant monolayer, plus related 332 
molecular interaction, led to increased rigidity and a more rapid increase in the surface pressure 333 
term.  The net effect is the presentation of the condensed / solid phases at an earlier point in time. 334 
This is due to an increase in the number of molecules over a constant surface area. The process by 335 
which the drug molecule can partition into the monolayer and diffuse out can also be explained by 336 
the inhomogeneous solubility-diffusion mechanism [34].  This involves a three-step process by which 337 
the molecule partitions in, diffuses within the structure and to an extent partitions out, which depends 338 
on thermodynamic driving forces of the complete system under investigation. 339 
On delivery of the drug-containing solutions (e.g. 0.02mcg/ml) to the supporting aqueous subphase, 340 
a further dilution took place in the average volume of 41ml (n=3) of ultrapure water held within the 341 
Langmuir trough.  Upon addition of 1ml of the 0.02mcg, this would equate to a final concentration of 342 
4.76x10-4 mcg/ml of salbutamol sulphate in the subphase.  Furthermore, an addition of 0.01mcg and 343 
0.04mcg would further dilute the drug to a concentration to 2.38x10-4 mcg/ml and 9.52x10-4 mcg/ml, 344 
respectively.   345 
 
Surface 
Area (%) 
 
Baseline 
(Monolayer) 
 
Salbutamol 
(0.01mcg) 
 
Salbutamol 
(0.02mcg) 
 
Salbutamol 
(0.04mcg) 
80 0.0268 0.0163 0.0101 0.0082 
70 0.0306 0.0187 0.0115 0.0093 
60 0.0358 0.0218 0.0135 0.0109 
50 0.0429 0.0261 0.0162 0.0130 
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This indicates that with highly diluted drug concentrations scope exists for partitioning into the 346 
monolayer, which is shown by translocation of the curves to the right.  Indeed, this effect was reported 347 
by Jablonowska and Bilwicz during 2007 where the group demonstrated that ibuprofen diluted to 348 
concentrations of 2x10-5- 2x10-4 M caused changes in the compressibility of a surfactant monolayer 349 
with partitioning still occurring at low concentrations [35]. 350 
 351 
3.2 Langmuir Isocycles 352 
 353 
 354 
Average Langmuir compression-expansion cycles of the simulated pulmonary surfactant monolayer 355 
system at pH 7 pre- and post-salbutamol sulphate addition are presented in Figure 3.  The data 356 
presented are averages of three replicates of the same. 357 
 358 
Figure 3. Average LaŶgŵuir π-A isocycles for the mixed surfactant system supported on an ultrapure water 359 
subphase with a salbutamol sulphate concentration of 4.76x10-4 mcg/ml at pH 7.  In each case, 3 repeats were 360 
acquired and points are the mean with error bars of one standard error in the mean.  The experiments were 361 
conducted at a temperature of 20°C  1oC. 362 
 363 
During Langmuir pressure – area isocycle generation, initial pre-conditioning inward and outward 364 
sweeps were executed (n=4).  The purpose of this procedure was to prepare the conformation of the 365 
mixed monolayer system to best represent that noted within the (deep) human lung.  Clearly, this 366 
approach differs from a single compression isotherm in that the constituent molecules are arranged 367 
more favourably and typical of the physiologically relevant scenario.   368 
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This pre-conditioning stage and removal of associated early phase traces (n=4) results in the 369 
elimination of the solid phase plateau noted in single Langmuir pressure – area isotherms (i.e. those 370 
shown in Figure 2). 371 
On monolayer cycling, the maximum surface pressure for the mixed surfactant system was 54.4mN/m.   372 
However, on addition of salbutamol sulphate this value increased to 57.6mN/m; equating to a 6% 373 
increase in the term.  Once again, the data indicate that further to the addition of salbutamol sulphate 374 
to the supporting aqueous media the monolayer becomes expanded in nature (i.e. the LaŶgŵuiƌ π-A 375 
isocycles translocate to the right).  In a similar fashion to that outlined above, the compressibility term 376 
also decreased following salbutamol sulphate administration.  Here, the baseline value of 377 
0.0288mN/m decreased to 0.0203mN/m, representing a 30% reduction in the parameter indicative of 378 
reduced flexibility, compressibility and increased rigidity of the monolayer.  379 
On completion of the Langmuir isocycle experiments, deviation in the gradient of the trace confirmed 380 
amphiphilic molecule phase transitions (i.e. movement from the gaseous phase through to the 381 
expanded and condensed phases and ultimately the solid phase).  On moving from the gaseous phase 382 
to the solid phase, there is a related increase in molecular order.  As such, at low surface pressures 383 
the monolayer exhibits a certain level of disorder with some spacing between constituent surface 384 
active molecules.  At the higher surface pressure, the monolayer is decidedly ordered and a tighter 385 
molecular packing of DPPC, POPG and PA has occurred resulting in a solid phase transition [36].  Thus, 386 
the very state of the surfactant film will govern the propensity of the dissolved drug molecules to 387 
partition into the ensemble. 388 
The injection of salbutamol sulphate (0.02mcg/ml) into the supporting aqueous subphase caused the 389 
gradient of the Langmuir isocycle to become steeper.  The data indicate that the phase transitions 390 
occur at an earlier point in time, as compared to the baseline.  The result can be attributed to an 391 
increase in the number of molecules across the two-dimensional plane (i.e. the insertion of drug 392 
molecules into the surfactant monolayer).  It is the very presence of drug molecules within the system 393 
that leads to a more rapid phase transformation and resultant tighter packing at an earlier stage.  Such 394 
packing causes the presentation of the solid phase sooner than compared to the baseline.  395 
 396 
 397 
 398 
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Monolayer collapse occurs where lipid components become unstable after maximum surface pressure 399 
has been achieved [37]; naturally this situation should be avoided within the laboratory setting.  In 400 
terms of the Langmuir isotherm baseline data, the simulated pulmonary surfactant monolayer 401 
collapsed at the maximum surface pressure of 49.5mN/m.  However, typical collapse pressure for a 402 
simulated pulmonary surfactant monolayer (i.e. Curosurf® [38]) would be approximately 70mN/m.  403 
This parameter is influenced by factors such as the operating temperature and the lipid composition.  404 
Thus, we suggest that the lower maximum surface pressure present herein was a combined function 405 
of the operating temperature (i.e. 21C), monolayer composition (i.e. only DPPC, POPG and PA), plus 406 
monolayer pre-conditioning stages that involved four repeated compression – expansion events.   407 
It is anticipated that to some extent drug partitioning within a surfactant film is reversible as re-408 
spreading occurs on barrier expansion (i.e. representative of inhalation) [37]; particularly at the higher 409 
percentage trough areas.  Excess lipid material is removed from the subphase into the surface 410 
associated reservoir during compression at exhalation. The material is usually composed of 411 
uŶsatuƌated lipid ĐoŵpoŶeŶts ǁheƌe this pheŶoŵeŶoŶ illustƌates the ŵoleĐules aƌe ďeiŶg ͚sƋueezed 412 
out͛ fƌoŵ the ŵoŶolayeƌ. As a ƌesult, satuƌated lipid ĐoŵpoŶeŶts at the iŶteƌfaĐe oďtaiŶ loǁ suƌfaĐe 413 
tensions in vivo. 414 
3.3 Langmuir Surface Pressure – Time Analysis 415 
 416 
During this work, consideration was given to how the physical state of a simulated pulmonary 417 
surfactant monolayer (i.e. expanded or compressed) can influence drug partitioning behaviour.  To 418 
this end, Langmuir surface pressure – time plots were generated.  The penetration pressure () [17, 419 
39] data for both the expanded and compressed systems are presented in Figure 4. 420 
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 421 
Figure 4. Average Langmuir penetration pressure – time plots for the systems under consideration.  Each data 422 
point arises from three repeats of the same experiment. Standard error of the mean bars have been included 423 
within the plot, however visibility is limited due to low variability in the data sets.  The surface pressure term has 424 
an impact on the partitioning behaviour of salbutamol, with the lower surface pressure offering greater scope 425 
for drug insertion into the two-dimensional film.  All data are acquired at pH 7 and a temperature of 20°C  1oC. 426 
 427 
The addition of salbutamol sulphate (0.02mcg) to the underside of the simulated pulmonary 428 
surfactant monolayer caused an increase in the surface pressure term in both cases with respect to 429 
time.  Upon inspection of the data presented in Figure 4, it is evident that the change in surface 430 
pressure () is greater in the case of the more expanded system (i.e. 10mN/m) and this directly aligns 431 
with the relaxed physical arrangement of the surfactant molecules.  Thus, there is a greater propensity 432 
for drug molecules to partition into the two-dimensional surfactant film at the lower surface pressure 433 
(i.e. inhalation end-point).  We emphasise that at the target pressure of 50mN/m, the rate of drug 434 
partitioning was slower albeit still taking place (i.e. P=0.0014: Langmuir surface pressure – time data, 435 
not shown).  Whilst there would be tight molecular order at this pressure, absolute compression does 436 
not occur and consequently there is still the opportunity for salbutamol to interact constructively with 437 
and partition into the monolayer.  438 
 439 
 440 
 441 
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The data confirm that the physical state of the monolayer can have a significant bearing on the 442 
partitioning behaviour of solubilised drug molecules within the underlying vicinity.  Typically, the polar 443 
head groups of DPPC, POPG and PA are situated deep within the supporting aqueous media at low 444 
surface pressures [40, 41].  Thus, a solubilised drug molecule (i.e. arising post drug particle dissolution) 445 
can readily interact with the components of the surfactant monolayer and subsequently associate 446 
with or penetrate into the two-dimensional structure.  It is to be expected that the extent of drug 447 
partitioning is likely to be greater at a lower surface pressure (i.e. the point of inhalation) due to the 448 
increased likelihood of accessible regions [42, 43] for molecular insertion.   449 
Indeed, when we consider the two-dimensional arrangement of the components of a model lung 450 
surfactant (i.e. DPPC, POPG and PA) throughout the course of compression and expansion, there is 451 
high level of certainty that ͚accessible regions͛ will present to in turn promote drug partitioning.  At 452 
this juncture, it is appropriate to refer to the work conducted by Bringezu and colleagues in 2003 who 453 
probed the impact of environmental tobacco smoke on the primary lipid species of lung surfactant 454 
[9].  During the work, the group applied fluorescence microscopy to observe the changes in monolayer 455 
structure as lateral compression was applied across the plane.  With regard to their pristine system 456 
(i.e. identical to that applied during this work), low surface pressures were linked to the presentation 457 
of condensed or tightly packed DPPC / PA regions within expanded or more relaxed DPPC / POPG areas 458 
consistently visible throughout the surfactant film as a whole.  The fluorescent dye applied during the 459 
work preferentially distributed itself into the disordered DPPC / POPG regions.  As the surface pressure 460 
was ramped towards the collapse point, the number of solid phase domains increased.  Thus, at the 461 
higher surface pressures the monolayer structure became much more ordered.  The data presented 462 
within the piece confirmed that a surfactant monolayer composed of primary lipid species exhibits 463 
non-uniform packing throughout, a feature to be anticipated at the alveolar air-liquid interface within 464 
the body. 465 
The apparent lack of homogeneity across a lung surfactant film does lend strong support to the 466 
ĐoŶĐept of ͚aĐĐessiďle aƌeas͛ to promote drug partitioning, as detailed by Vilallonga and Phillips in 467 
1978 [39].  This work considered how the anthracycline glycoside antibiotic doxorubicin associated 468 
with phospholipid monolayers located at the air-liquid interface.  On application of the accessible area 469 
calculation (i.e. � = � − ���) it was established that the condensed monolayer had an average 7% 470 
region of access for dissolved drug molecules, as compared to the less condensed monolayer of 33% 471 
availability for the same.   472 
 473 
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The net effect was a greater increase in the surface pressure term for the more relaxed monolayer 474 
system (i.e. there was more area accessible for drug partitioning and as such more drug molecules 475 
were able to penetrate into the structure and increase the surface pressure).  The group also 476 
demonstrated an increase in the surface pressure term in all cases following the injection of drug 477 
suďstaŶĐe ďeŶeath the ŵoŶolayeƌ stƌuĐtuƌe.  The ƌesult ǁas asĐƌiďed to the ͚osŵotiĐ appƌoaĐh͛ 478 
leading to an increase in the number of molecular entities at the interface.   479 
A similar principle was applied by Krill and co-workers in 1998 who considered the partitioning 480 
ďehaǀiouƌ of ǀaƌious β-antagonists (e.g. propranolol, oxprenolol, metoprolol and nadolol) when 481 
placed in an aqueous environment beneath Langmuir monolayers composed of 482 
dimyristoylphosphatidylcholine [17].  Within the study, clear reference was made to the fact that all 483 
molecules demonstrated surface activity, irrespective of solution concentration.  Importantly, 484 
movement into condensed phases of the monolayer structure was noted, which links with the findings 485 
presented herein (i.e. a notable change in the presented penetration pressure at the higher value of 486 
50mN/m).  Thus, throughout tidal breathing one would expect therapeutic entities to associate with 487 
and partition into lung surfactant at the alveolar air-liquid interface, irrespective of the surface 488 
pressure placed on the endogenous material at any one time.  The propensity of this process heavily 489 
depends upon the chemical properties of the administered molecule(s).  For instance, Krill and 490 
colleagues demonstrated that propranolol exhibited the greatest degree of monolayer penetration 491 
followed by metoprolol, oxprenolol and finally nadolol.  Thermodynamic aspects are central to drug 492 
insertion into a surfactant film.  For example, Krill noted that propranolol partitioning into the 493 
monolayer structure was enthalpically and entropically driven, and this contrasted sternly with 494 
nadolol which was mainly enthalpically driven whilst being strongly entropically hindered.  It would 495 
appear that two key aspects dominate the interaction as a whole; namely, modification to the 496 
monolayer structure across the plane plus the physical movement of drug molecules into the lipid 497 
layer.   498 
Variation in the monomolecular structure results further to drug partitioning with either the drug 499 
causing expanded regions to become more condensed in nature via insertion within accessible areas 500 
or direct interaction between drug molecule and surfactant components, as modelled herein.  Such 501 
modification to the surfactant film in the (deep) lung can influence structure-function activity [10], 502 
however in general terms the surfactant film appears robust and resilient to external stressors (i.e. 503 
drug substances and environmental toxins [43]) and this allows it to fulfil its crucial biological function. 504 
 505 
 506 
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3.4 Molecular Modelling 507 
 508 
3.4.1 Salbutamol Interaction with Surfactant Film Components  509 
 510 
The electrostatic potential surfaces (EPSs) of the polar head groups associated with each surfactant 511 
molecule (i.e. DPPC, POPG and PA) along with salbutamol were calculated via the quantum mechanics 512 
software package Gaussian09. The hydrophobic tails were abbreviated to a methyl group, to avoid 513 
studying conformations that would not be relevant to the monolayer conditions. A set of up to 10 514 
conformations of each molecule was created by omega and each was optimized with RHF/6-31G*.  515 
The lowest energy conformation was then identified and its electrostatic potential projected onto a 516 
surface of the molecule (the total electron density cut at 0.0004 electrons/Å3). In these electrostatic 517 
potential maps, red indicates strongly negative regions, yellow less negative regions, blue strongly 518 
positive regions and cyan less positive regions.  Regions coloured green have an approximately neutral 519 
electrostatic potential.  To aid analysis we provide arrows to highlight important regions of interaction 520 
and place the linkage to the hydrophobic tails at the top of each figure.   521 
In the case of salbutamol, one end of the molecule is generally hydrophobic (the aromatic ring) and 522 
this is assumed to prefer contact with the hydrophobic tails of the monolayer and so is also placed at 523 
the top of the figure. The EPSs for salbutamol are shown for the molecule in its predominant cationic 524 
form.  Similar images for the zwitterionic form, in which the phenol is deprotonated, were also 525 
generated but represent only a small contribution (i.e. <1%) to the population of molecules and so are 526 
not shown here. 527 
 528 
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 529 
 530 
Figure 5. EPS calculations of salbutamol and DPPC (front and rear views provided) with key interaction sites 531 
determined for pH 7. 532 
When in proximity to DPPC, the predominant component of the monolayer, the two are likely to 533 
interact in a way that maximises both electrostatic and hydrophobic interactions.  As shown in Figure 534 
5, when the major interacting face of salbutamol presents a large positively charged patch in such a 535 
way that it can interact with the negatively charged patch to the major interacting face of DPPC, this 536 
naturally places the hydrophobic aromatic ring in proximity with the hydrophobic tails of DPPC.  When 537 
the molecules are paired like this, it can be seen that the opposite face of each molecule are also 538 
complementary, albeit with less extreme electrostatic components.  When the interactions with the 539 
other components of the monolayer are considered, as shown in Figure 6, it is clear that there are a 540 
range of positions that salbutamol can adopt to allow it to maximise beneficial interactions with the 541 
molecules around it, regardless of which molecules those are.  The optimum position in each case 542 
involves a different degree of penetration into the monolayer.   543 
With POPG, the interactions are likely to be best when the salbutamol penetrates deeply into the 544 
monolayer whereas with PA, the opposite is the case.  This differing behaviour will cause different 545 
effects on the monolayer.  When amongst the head groups (as with PA), the salbutamol is promoting 546 
the movement apart of the hydrophobic tails and making the monolayer more like the gas phase.  547 
Whereas, when the salbutamol penetrates amongst the tail groups (as with POPG and DPPC), it 548 
compresses those groups making the system more like the solid phase. 549 
 550 
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 551 
Figure 6. EPS calculations of salbutamol, POPG and PA with key interaction sites determined for pH 7. 552 
These hydrophobic and electrostatic forces of attraction explain the consistent shift of the Langmuir 553 
isotherm and isocycle data as compared to the baseline, which relates to expansion of the monolayer. 554 
The spontaneous movement of drug molecules into the monolayer and the formation of molecular 555 
interactions between the molecules encourage and facilitate drug partitioning and insertion. Thus, the 556 
monolayer is less compressible and highly rigid resulting in an expanded character. 557 
4. Conclusion  558 
 559 
 560 
This study has considered the partitioning behaviour of salbutamol (sulphate) when in close proximity 561 
to fundamental components of endogenous pulmonary surfactant.  The work confirms the suitability 562 
of Langmuir monolayers to serve as model interfaces to further current understanding within this 563 
relatively under-researched field.  The data indicate that the drug molecule of interest impacted upon 564 
the activity of simulated pulmonary surfactant during compression and expansion phases; reflective 565 
of the human breathing cycle.  The injection of salbutamol sulphate to the underside of the lipid film 566 
(i.e. to reflect drug availability post particle dissolution) caused general expansion of the surface active 567 
material and decreased the compressibility term.  Drug partitioning behaviour was highly dependent 568 
on the physical state of the surfactant monolayer, where the rate of partitioning was greater at the 569 
lower surface pressure that represented greater molecular disorder.   570 
POPG	 PA	
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Naturally, potential exists to exploit the drug partitioning process in lung surfactant films for 571 
therapeutic advantage.  The sustained presence of a drug molecule(s) in the pulmonary space could 572 
be of clear benefit of the patient in reducing the frequency of daily dosing.  Indeed, this approach may 573 
be viewed as an advanced modified release strategy (i.e. non-classical) that is solely dependent on 574 
chemical complementarity between all species involved.    575 
 576 
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